Sources and References

FDA. “FDA Approves Journavx, a Non-Opioid Treatment for Acute Pain.” FDA, 2025, FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain | FDA

Northwestern University. “FDA’s Non-Opioid Pain Drug Approval is a Breakthrough.” Northwestern News, 2025, FDA approval of non-opioid pain drug is ‘a major breakthrough,’ expert says: For Journalists – Northwestern University

Science. “New Pain Medication Approved by FDA After 25 Years.” Science, 2025, Nonopioid drug for acute pain wins FDA approval | Science | AAAS

Vertex Pharmaceuticals. “Vertex Announces FDA Approval of Journavx.” Vertex News, 2025, Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain | Vertex Pharmaceuticals Newsroom

Nature. “FDA Approves First Non-Opioid Painkiller in Decades.” Nature, 2025, FDA approves new non-opioid pain drug

.

Pages: 1 2